Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 17

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 17
---
. We believe that our non-viral DNA technology may be a viable alternative
to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular versatility that allows
for complex modifications to potentially improve activity and safety.

The
biocompatibility of these polymers reduces the risk of adverse immune response, thus allowing for repeated administration. Compared to
naked DNA or cationic lipids, we believe that our delivery systems are generally more efficient, cost effective and have a more favorable
safety profile. We believe that these advantages place Imunon in a position to capitalize on this technology platform.

17

THERAPLAS
MODALITY: IMNN-001 DEVELOPMENT PROGRAM

Ovarian
Cancer Overview

Ovarian
cancer is the most lethal of gynecological malignancies among women with more than 60% of women dying within five years of diagnosis.
This poor outcome is due in part to the lack of effective prevention and early detection strategies. There were approximately 20,000
new cases of ovarian cancer in the U.S. in 2021 with an estimated 13,000 deaths. Mortality rates for ovarian cancer declined very little
in the last 40 years due to the unavailability of detection tests and improved treatments. Most women with ovarian cancer are not diagnosed
until Stages III or IV, when the disease has spread outside the pelvis to the abdomen and areas beyond, causing swelling and pain. With
the five-year survival rates for Stages III and IV at 41% and 20%, respectively, there remains a need for a therapy that not only reduces
the recurrence rate but also meaningfully improves overall survival. Patients whose cancer recurs or progresses after initially responding
to surgery and first-line chemotherapy have been divided into one of the two groups based on the time from completion of platinum therapy
to disease recurrence or progression. This time period is referred to as platinum-free interval. The platinum-sensitive group has a platinum-free
interval of longer than nine months. This group generally responds to additional treatment with platinum-based therapies. The platinum
resistant group has a platinum-free interval of shorter than nine months and is resistant to additional platinum-based treatments. Pegylated
liposomal doxorubicin, topotecan, and bevacizumab are the only approved second-line therapies for platinum-resistant ovarian cancer.
The overall response rate for these therapies is 10% to 20% with median overall survival (“OS”) of 11 to 12 months.